Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menü

Klinische Studien von BMS suchen
BMS Completed Study icon

Completed

Studien-Nr. IM103-399  |   NCT03375138

A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes

Warnsymbol
Diese Studie ist nun abgeschlossen.  Sobald die Ergebnisse verfügbar sind, werden sie auf ClinicalTrials.gov veröffentlicht.
Studienergebnisse anzeigen
Sie können überprüfen, ob eine andere klinische Studie für Sie infrage kommt, indem Sie auf die Schaltfläche „Prüfen Sie, ob eine Studie für Sie infrage kommt“ klicken
Kommt die Studie für Sie infrage

Überblick

This study compares the movement of Belatacept drug products, whose active pharmaceutical ingredient has been manufactured by 2 different processes, into, through and out of the body (pharmacokinetics/PK) of healthy volunteers. Eligible participants will be randomly assigned to one of two groups, and will receive a single dose of a belatacept product once during a 4-day stay at a study site.

Unterstützen Sie uns dabei, Ihre Nutzung der Website zu optimieren! Teilen Sie Ihr Feedback mit unserem Team bei BMS Clinical Trials, um die Nutzung der Webseite, Ihre Erfahrungen und die anderer zu verbessern. Vielen Dank!